Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
Cash to Debt No Debt
ONCY's Cash to Debt is ranked higher than
81% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. ONCY: No Debt )
ONCY' s 10-Year Cash to Debt Range
Min: 45.91   Max: No Debt
Current: No Debt

Interest Coverage No Debt
ONCY's Interest Coverage is ranked higher than
69% of the 574 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ONCY: No Debt )
ONCY' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 2
Z-Score: -9.34
M-Score: -3.42
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
ROE (%) -103.98
ONCY's ROE (%) is ranked higher than
58% of the 1134 Companies
in the Global Biotechnology industry.

( Industry Median: -34.93 vs. ONCY: -103.98 )
ONCY' s 10-Year ROE (%) Range
Min: -164.19   Max: -26.92
Current: -103.98

-164.19
-26.92
ROA (%) -84.60
ONCY's ROA (%) is ranked higher than
55% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: -28.51 vs. ONCY: -84.60 )
ONCY' s 10-Year ROA (%) Range
Min: -125.21   Max: -25.07
Current: -84.6

-125.21
-25.07
ROC (Joel Greenblatt) (%) -3978.66
ONCY's ROC (Joel Greenblatt) (%) is ranked higher than
59% of the 1212 Companies
in the Global Biotechnology industry.

( Industry Median: -442.83 vs. ONCY: -3978.66 )
ONCY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -15749.15   Max: -455.21
Current: -3978.66

-15749.15
-455.21
EBITDA Growth (%) -4.40
ONCY's EBITDA Growth (%) is ranked higher than
76% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: -4.60 vs. ONCY: -4.40 )
ONCY' s 10-Year EBITDA Growth (%) Range
Min: -7.2   Max: 42.6
Current: -4.4

-7.2
42.6
EPS Growth (%) -10.50
ONCY's EPS Growth (%) is ranked higher than
74% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. ONCY: -10.50 )
ONCY' s 10-Year EPS Growth (%) Range
Min: -10.5   Max: 21.9
Current: -10.5

-10.5
21.9
» ONCY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

ONCY Guru Trades in Q4 2013

Jean-Marie Eveillard 427,200 sh (unchged)
Jim Simons 19,200 sh (-39.05%)
» More
Q1 2014

ONCY Guru Trades in Q1 2014

Jim Simons 23,600 sh (+22.92%)
Jean-Marie Eveillard 427,200 sh (unchged)
» More
Q2 2014

ONCY Guru Trades in Q2 2014

Jim Simons 36,000 sh (+52.54%)
Jean-Marie Eveillard 188,600 sh (-55.85%)
» More
Q3 2014

ONCY Guru Trades in Q3 2014

Jean-Marie Eveillard Sold Out
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ONCY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2014-09-30 Sold Out $0.563 - $1.66 $ 0.7-45%0
Jean-Marie Eveillard 2014-06-30 Reduce -55.85%$1.23 - $1.99 $ 0.7-51%188600
Jean-Marie Eveillard 2013-03-31 New Buy$2.99 - $4.67 $ 0.7-81%450000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.50
ONCY's P/B is ranked higher than
76% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 5.76 vs. ONCY: 4.50 )
ONCY' s 10-Year P/B Range
Min: 1.25   Max: 18.75
Current: 4.5

1.25
18.75
EV-to-EBIT -2.70
ONCY's EV-to-EBIT is ranked higher than
78% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ONCY: -2.70 )
ONCY' s 10-Year EV-to-EBIT Range
Min: -34.2   Max: 0.4
Current: -2.7

-34.2
0.4
Current Ratio 5.32
ONCY's Current Ratio is ranked higher than
75% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. ONCY: 5.32 )
ONCY' s 10-Year Current Ratio Range
Min: 2.21   Max: 142.02
Current: 5.32

2.21
142.02
Quick Ratio 5.32
ONCY's Quick Ratio is ranked higher than
76% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.53 vs. ONCY: 5.32 )
ONCY' s 10-Year Quick Ratio Range
Min: 2.21   Max: 142.02
Current: 5.32

2.21
142.02

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.00
ONCY's Price/Net Cash is ranked higher than
89% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 64.50 vs. ONCY: 5.00 )
ONCY' s 10-Year Price/Net Cash Range
Min: 2.44   Max: 24.08
Current: 5

2.44
24.08
Price/Net Current Asset Value 5.00
ONCY's Price/Net Current Asset Value is ranked higher than
88% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 34.97 vs. ONCY: 5.00 )
ONCY' s 10-Year Price/Net Current Asset Value Range
Min: 2.44   Max: 24.08
Current: 5

2.44
24.08
Price/Tangible Book 4.70
ONCY's Price/Tangible Book is ranked higher than
81% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9.12 vs. ONCY: 4.70 )
ONCY' s 10-Year Price/Tangible Book Range
Min: 2.06   Max: 22.36
Current: 4.7

2.06
22.36
Earnings Yield (Greenblatt) -37.00
ONCY's Earnings Yield (Greenblatt) is ranked higher than
52% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -6.40 vs. ONCY: -37.00 )
ONCY' s 10-Year Earnings Yield (Greenblatt) Range
Min: -37   Max: 2281.4
Current: -37

-37
2281.4

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:ONC.Canada, ONY.Germany
Oncolytics Biotech, Inc., was incorporated on April 2, 1998 under the Business Corporations Act (Alberta) as 779738 Alberta Ltd. The Company is a development stage biopharmaceutical company that focuses on the discovery and development of pharmaceutical products for the treatment of cancers. The Company focused on the development of oncolytic viruses for use as cancer therapeutics. Its product, REOLYSIN, a proprietary formulation of the human reovirus, is in late stage (Phase III) clinical testing in head and neck cancers.
» More Articles for ONCY

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Nasdaq stocks posting largest volume increases Nov 26 2014
Media Advisory - Oncolytics Biotech® Inc. to Participate in the Stifel 2014 Healthcare Conference Nov 18 2014
Media Advisory - Oncolytics Biotech® Inc. to Participate in the Stifel 2014 Healthcare Conference Nov 18 2014
Media Advisory - Oncolytics Biotech® Inc. to Participate in the Stifel 2014 Healthcare Conference Nov 18 2014
Oncolytics Biotech® Inc. Announces Third Quarter 2014 Results Nov 06 2014
Oncolytics Biotech® Inc. Announces Third Quarter 2014 Results Nov 06 2014
Oncolytics Biotech® Inc. Announces Receipt of Nasdaq Notice of Deficiency Nov 04 2014
Oncolytics Biotech® Inc. Announces Receipt of Nasdaq Notice of Deficiency Nov 04 2014
Oncolytics Biotech® Inc. Announces Receipt of Nasdaq Notice of Deficiency Nov 04 2014
Geron Corporation (GERN) Looks Strong: Stock Up 25.6% Nov 04 2014
Oncolytics Biotech (ONCY) Looks Strong: Stock Up 21.9% Nov 03 2014
Oncolytics Biotech (ONCY) Looks Good: Stock Soars 26% Oct 30 2014
Novavax (NVAX) in Focus: Stock Rises 13% Oct 28 2014
Oncolytics Biotech® Inc. Announces Entry Into $20 Million "At-The-Market" Equity Distribution... Oct 24 2014
Oncolytics Biotech® Inc. Announces Entry Into $20 Million "At-The-Market" Equity Distribution... Oct 24 2014
Oncolytics Biotech® Inc. Announces Entry Into $20 Million "At-The-Market" Equity Distribution... Oct 24 2014
Merrimack Pharmaceuticals (MACK) Looks Strong: Stock Up 8.6% Oct 24 2014
Oncolytics Biotech® Inc. Announces Amendment to Common Share Purchase Agreement with Lincoln Park... Oct 20 2014
Oncolytics Biotech® Inc. Announces Amendment to Common Share Purchase Agreement with Lincoln Park... Oct 20 2014
Oncolytics Biotech® Inc. Announces Amendment to Common Share Purchase Agreement with Lincoln Park... Oct 20 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK